Curative Analysis of Gemcitabine Plus Cisplatin for First Line Treatment of Advanced Non-small Cell Lung Cancer

ObjectiveTo evaluate the curative effect and toxicities of gemcitabine plus cisplatin to therapy patients with advanced non-small cell lung cancer and identify factors to predict prognosis. Methods113 patients staged IIIB~IV NSCLC were received gemcitabine plus cisplatin as first line treatment. Response rates and toxicities were evaluated in patients who completed at least two cycles of chemotherapy. Progression free survival(PFS) and Overall survival(OS) were estimated using the Kaplan-Meier estimator. Cox regression analysis was used to identfy potential prognosis factors. ResultsThe overall response rate was 43.8%, and the baseline characteristics could not predict the efficacy. The median PFS and OS were 6.7 months and 16.7 months respectively. The predominant toxicities were grade 1 or 2 hematologic toxicities and gastrointestinal reaction. Multivariate analysis revealed that smoking status, numbers of metastasis, liver metastasis and chemotherapy cycles were independent prognosis factors. ConclusionGemcitabine plus cisplatin showed significant efficacy with less toxicities as first line treatment for advanced NSCLC. Smoking, liver metastasis and more than one metastatic sites were poor prognostic factors. Four to six cycles of chemotherapy were the optimal selection.